Patents by Inventor Xiangao Huang

Xiangao Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9259399
    Abstract: The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: February 16, 2016
    Assignee: Cornell University
    Inventors: Selina Chen-Kiang, Maurizio Di Liberto, Xiangao Huang
  • Publication number: 20140031325
    Abstract: Provided herein are methods for the treatment of multiple myeloma, wherein the methods comprise administration of lenalidomide and administration of a second active agent such as a CDK inhibitor.
    Type: Application
    Filed: December 5, 2011
    Publication date: January 30, 2014
    Applicant: Celgene Corporation
    Inventors: Blake Bartlett, Maurizio Di Liberto, Xiangao Huang, Selina Chen-Kiang
  • Publication number: 20110009353
    Abstract: The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.
    Type: Application
    Filed: October 1, 2008
    Publication date: January 13, 2011
    Inventors: Selina Chen-Kiang, Maurizio Di Liberto, Xiangao Huang